Get started
Author

Nina Stojcheva

Observed names: N Stojcheva, N. Stojcheva
ORCID: 0000-0001-8652-8356
Observed ORCID: 0000-0001-8652-8356
OpenAlex ID: A5059289199
MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM
2016 · Nina Stojcheva, Gennadi Schechtmann, et al. · Oncotarget · 62
PDF
MiR‐16‐5p is frequently down‐regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy
2018 · A. Krell, M. Wolter, et al. · Neuropathology and Applied Neurobiology · 58
PDF
Transcriptional control of O6‐methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma
2018 · Caroline Happold, Nina Stojcheva, et al. · Journal of Neurochemistry · 35
PDF
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
2019 · Alessandra Curioni-Fontecedro, Jean Yannis Perentes, et al. · British Journal of Cancer · 12
PDF
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
2026 · Neeltje Steeghs, Carlos Gomez-Roca, et al. · Nature Cancer · 10
PDF
Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.
2024 · Neeltje Steeghs, Carlos A. Gomez-Roca, et al. · Journal of Clinical Oncology · 8
Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study
2023 · Nina Stojcheva, Stacy Gladman, et al. · British Journal of Clinical Pharmacology · 6
PDF
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
2023 · Carlos A. Gomez-Roca, Neeltje Steeghs, et al. · Journal of Clinical Oncology · 5
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study
2024 · Jeff Kingsley, Nagalingeswaran Kumarasamy, et al. · Open Forum Infectious Diseases · 3
1130. Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial
2022 · Luis Abrishamian, Marc Bonten, et al. · Open Forum Infectious Diseases · 2
PDF
612 Comprehensive biomarker analyses from a phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic DARPin
2024 · Jennifer Krieg, Vaia Stavropoulou, et al. · Journal for ImmunoTherapy of Cancer · 1
1475 A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors
2022 · Hilde De Winter, Elena Fernandez, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors
2023 · Carlos Gomez-Roca, Neeltje Steeghs, et al. · Journal for ImmunoTherapy of Cancer
PDF
Faster clinical recovery with ensovibep compared to placebo in patients with mild-to-moderate COVID-19: interim results from the EMPATHY Phase 2 trial
2022 · R Chandra, L Abrishamian, et al. · European Respiratory Journal
SAKK 57/16 nab-paclitaxel and gemcitabine in soft tissue sarcoma (NAPAGE): Results from the phase I part of a phase I/II trial
2019 · A. Digklia, C. Britschgi, et al. · Annals of Oncology
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK
2017 · A. Curioni-Fontecedro, H.-B. Ris, et al. · Annals of Oncology
PDF
Works count: 16
Citation count: 203
H-index: 6
I10-index: 5
Year
Topic
Type